Our Product Pipeline

Botanix’s product pipeline includes Sofpironium Bromide for which we expect to file a New Drug Application (NDA) with the FDA in 2H2022.  Three other advanced clinical-stage programs utilise a synthetic form of cannabidiol for the topical treatment of a range of dermatology and antimicrobial indications which have completed, or are currently undergoing Phase 2 studies.

Indication Product Phase 1 Phase 1b Phase 2 Phase 3 Approved Status
Axillary Hyperhidrosis (excessive underarm sweating) Sofpironium Bromide
FDA approval filing planned 2H 2022
Moderate to severe acne BTX 1503
Pending Phase 3 study
Rosacea BTX 1702
Phase 2b study underway
Atopic dermatitis BTX 1204A
Canine proof-of-concept study underway
Antimicrobial BTX 1801
Phase 2b study (successfully completed).
Phase 2b study (pending).